Imprimis Pharmaceuticals, Inc. (IMMY) At $1.92 Forms Bottom; Versartis Has 1.29 Sentiment

Versartis, Inc. operates as an endocrine-focused biopharmaceutical firm in the United States. The company has market cap of $73.41 million. The firm is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It currently has negative earnings. It develops drug candidates that it has licensed from Amunix Operating, Inc.

Imprimis Pharmaceuticals, Inc. (IMMY) formed multiple bottom with $1.84 target or 4.00% below today’s $1.92 share price. Imprimis Pharmaceuticals, Inc. (IMMY) has $39.43M valuation. The stock increased 14.29% or $0.24 during the last trading session, reaching $1.92. About 19.71M shares traded or 3923.38% up from the average. Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) has declined 2.70% since January 31, 2017 and is downtrending. It has underperformed by 19.40% the S&P500.

Among 2 analysts covering Imprimis Pharmaceuticals (NASDAQ:IMMY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Imprimis Pharmaceuticals had 3 analyst reports since July 23, 2015 according to SRatingsIntel. Zacks downgraded Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) on Monday, August 17 to “Hold” rating. The firm earned “Buy” rating on Monday, November 28 by Rodman & Renshaw. The rating was initiated by Sterne Agee CRT on Thursday, July 23 with “Buy”.

Investors sentiment decreased to 0.45 in Q3 2017. Its down 2.35, from 2.8 in 2017Q2. It turned negative, as 7 investors sold Imprimis Pharmaceuticals, Inc. shares while 4 reduced holdings. 1 funds opened positions while 4 raised stakes. 1.84 million shares or 35.54% less from 2.86 million shares in 2017Q2 were reported. Geode Management Ltd Liability owns 68,853 shares or 0% of their US portfolio. Financial Bank Of America Corporation De holds 1,500 shares or 0% of its portfolio. Ardsley Advisory Prtnrs holds 0% or 20,000 shares. Berson & Corrado Investment Ltd Liability Corp has invested 0.11% of its portfolio in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY). Granite Investment Prtnrs Ltd Co stated it has 127,214 shares. Northern Tru has invested 0% of its portfolio in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY). Blackrock Inc holds 71,194 shares. Royal Bank & Trust Of Canada holds 0% in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) or 720 shares. Virtu Limited Liability Corp has 15,692 shares for 0% of their portfolio. Vanguard Group holds 501,867 shares. Natl Bank Of New York Mellon Corporation reported 38,816 shares. Marathon Asset Lp has 0.14% invested in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY). Citigroup has invested 0% in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY). Bard Assoc stated it has 0.05% in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY).

Ratings analysis reveals 100% of Versartis’s analysts are positive. Out of 3 Wall Street analysts rating Versartis, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. VSAR was included in 3 notes of analysts from October 4, 2016. SunTrust initiated Versartis, Inc. (NASDAQ:VSAR) rating on Friday, December 2. SunTrust has “Buy” rating and $25.0 target. The stock has “Overweight” rating by Piper Jaffray on Tuesday, October 4. The firm has “Outperform” rating given on Tuesday, December 20 by Credit Suisse.

Alpinvest Partners B.V. holds 0.34% of its portfolio in Versartis, Inc. for 33,076 shares. Emory University owns 96,222 shares or 0.19% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.18% invested in the company for 1.89 million shares. The New York-based Ghost Tree Capital Llc has invested 0.14% in the stock. Sabby Management Llc, a New Jersey-based fund reported 707,300 shares.

Analysts await Versartis, Inc. (NASDAQ:VSAR) to report earnings on February, 20. They expect $-0.98 earnings per share, down 53.13% or $0.34 from last year’s $-0.64 per share. After $-1.40 actual earnings per share reported by Versartis, Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.

It closed at $2.05 lastly. It is up 103.18% since January 31, 2017 and is uptrending. It has outperformed by 86.48% the S&P500.

Since January 1, 0001, it had 0 buys, and 5 insider sales for $7.02 million activity.